{"entity":{"id":"nct00582075","kind":"trial","name":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","aka":[],"tldr":"A phase 2 trial of Gamma Knife in Brain metastases, run by University of Alabama at Birmingham, completed.","summary":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases is a phase 2 interventional study registered as NCT00582075 by University of Alabama at Birmingham, with 25 participants recorded, started 2002-07 and reaching its primary completion in 2008-10. Interventions recorded: temozolomide. Conditions recorded: Cancer, Brain Metastases.\n\nLinked to the technology Gamma Knife because the registry's title names it (\"gamma knife\") and Brain metastases among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00582075","url":"https://clinicaltrials.gov/study/NCT00582075"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["secondary-brain-tumours"],"sections":[],"technologies":["gamma-knife"],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00582075","phase":"2","setting":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases","sponsor":"University of Alabama at Birmingham","started":"2002-07","yearReported":2015,"enrolled":25,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants With Distant Brain Failure (DBF) at One Year","primary":true,"unit":"%","arms":[{"name":"Radiosurgery 15-24 Gy + Adjuvant Temozolomide","n":25,"value":37,"note":"Figures from the ClinicalTrials.gov results section (first posted 2015-09-17), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT00582075?tab=results"},{"endpoint":"Overall Survival","unit":"weeks","arms":[{"name":"Radiosurgery 15-24 Gy + Adjuvant Temozolomide","n":25,"value":31,"note":"range 11 to 104; Figures from the ClinicalTrials.gov results section (first posted 2015-09-17), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT00582075?tab=results"}]},"route":"/trials/nct00582075/","neighbours":{"cancer":[{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/"}],"technology":[{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}